Kodiak Sciences (KOD)

• Market cap: $234M
• 1 day: -6.12%
• 5 days: -11.88%
• 1 month: -40.67%
• 3 months: -24.58%
• 6 months: 59.50%
• Year to date: -48.38%
• 1 year: -14.59%
• 5 years: -92.36%
• 10 years: -56.20%
• Sector: Healthcare
• Industry: Biological Products, Except Diagnostic Substances

About: Kodiak Sciences Inc is a biopharmaceutical company specializing in novel therapeutics to treat high-prevalence retinal diseases. The product candidate of the company is KSI-301, which is a novel antibody biopolymer conjugate, in treatment-naive subjects with neovascular wet AMD.

Employees: 108

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

306% more capital invested

Capital invested by funds: $103M [Q3] → $418M (+$315M) [Q4]

101% more call options, than puts

Call options by funds: $543K | Put options by funds: $270K

77% more first-time investments, than exits

New positions opened: 23 | Existing positions closed: 13

7% more funds holding

Funds holding: 97 [Q3] → 104 (+7) [Q4]

4.93% more ownership

Funds ownership: 74.94% [Q3] → 79.86% (+4.93%) [Q4]

0% more repeat investments, than reductions

Existing positions increased: 30 | Existing positions reduced: 30

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

• Low target: $20 349% upside
• Avg. target: $20 349% upside
• High target: $20 349% upside

1 analyst rating

• positive: 1 100%
• neutral: 0 0%
• negative: 0 0%

Jefferies Michael Yee 10% 1-year accuracy 1 / 10 met price target

349% upside $20

Buy Upgraded

9 Dec 2024